SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guilford (GLFD) - Steadily Rising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (77)8/26/1997 11:50:00 PM
From: SteveG   of 496
 
<Yes. VRTX patent (5,654,332) cover broad class of the N-1,2-diketo-(Y)-(2S)-pyrrolidine-(X)- carboxylate derivatives which are very potent rotomase inhibitors (Ki~1-20 nM) with significant neurite outgrowth capability over control, alone or in combination with NGF (~50% increase).>

But don't these compounds also exhibit calcineurin inhibiting effects?

BTW, are you affiliated with Vertex?

Steve
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News